1. 抗体抑制剂

Inhibitory Antibodies

MCE Inhibitory Antibodies are monoclonal antibodies (mAbs) that have been extensively used in the hottest research areas, such as cancer, immunology and infection. These monoclonal antibodies (mAbs) bind monospecifically to certain cells or proteins, thus stimulating the immune system to attack the malignant tumor cells and preventing tumor growth by blocking specific cell receptors. They can inhibit PD-1, PD-L1, EGFR, VEGFR, TNF-alpha or other targets which are unusually active in diseases, such as non-Hodgkin lymphoma, Hemophilia A, renal cell carcinoma, Parkinson's disease and metastatic HER2-positive breast cancer. For example, by binding to VEGF, Bevacizumab prevents VEGF from interacting with its receptors, thereby inhibiting new vessel growth. Lambrolizumab targets the programmed cell death 1 (PD-1) receptor of lymphocytes. By preventing the binding of its ligands (PD-L1 and PD-L2), Lembrolizumab induces an antitumor immune response.

Inhibitory Antibodies (14):

Cat. No. Product Name Purity Concentration
  • HY-P9907
    Trastuzumab 99.30%
    Trastuzumab 是一种人源化单克隆抗体,其以高亲和力与 HER2 选择性结合。Trastuzumab 已被批准用于治疗 HER2 阳性转移性乳腺癌和 HER2 阳性胃癌。
  • HY-P9906
    Bevacizumab >99.0%
    Bevacizumab 是一种人源化的单克隆抗体,高亲和力且特异性地与所有 VEGF-A 结合。
  • HY-P9905
    Cetuximab 99.70%
    Cetuximab 是一种单克隆抗体,能够抑制 EGFR,SPR 方法测得 Cetuximab 对可溶性 EGFRKd 值为 0.201 nM;Cetuximab 具有高效的抗肿瘤作用。
  • HY-P9903
    Nivolumab 98.56%
    Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody to treat advanced (metastatic) non-small cell lung cancer.
  • HY-P9904
    Atezolizumab 98.98%
    Atezolizumab is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
  • HY-P9913
    Rituximab 99.85%
    Rituximab is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.
  • HY-P9902
    Pembrolizumab 98.56%
    Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
  • HY-P9908
    Adalimumab 98.12%
    Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
  • HY-P9912
    Pertuzumab 99.10%
    Pertuzumab, a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
  • HY-P9901
    Ipilimumab 99.88%
    Ipilimumab is a fully human monoclonal IgG1κ antibody against the cytotoxic T-lymphocyte antigen-4 (CTLA-4), an immune-inhibitory molecule expressed in activated T cells and in suppressor T regulatory cells.
  • HY-108730
    Avelumab
    Avelumab 是一个人 IgG1 抗 PD-L1 单克隆抗体,具有潜在的抗体依赖性细胞介导的细胞毒性作用。
  • HY-P9911
    Vedolizumab 99.64%
    Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
  • HY-P9910
    Obinutuzumab
    Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.
  • HY-P9909
    Ustekinumab
    Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.